France recently became the 24th country to authorise the sale of a cannabis-based medecine used to treat some of the worst effects of multiple sclerosis. Around half of France's 80-thousand MS sufferers could in theory benefit from the drug, known as Sativex, when it becomes available here in 2015. While many sufferers of severe spasticity are eager to try it, there is still some opposition to authorising cannabis in any shape or form.
